Biogen Turns A Corner As New Launches Offset MS Sales Declines
Overall Revenue Guidance Adjusted Positively
Executive Summary
Leqembi for early Alzheimer’s, Skyclarys for Friedreich’s ataxia and Zurzuvae for postpartum depression meet or exceed Biogen’s internal sales expectations.